# Biomerica Inc: overview BMRA · Nasdaq · CIK 73290 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31 Pages: [Overview](/companies/bmra.md) · [Financials](/companies/bmra/financials.md) · [Filings](/companies/bmra/filings.md) · [Insiders](/companies/bmra/insiders.md) Latest reported revenue: [$1.3m](/filings/0001493152-26-047271.md) for Q1 FY2027, three months to 2026-08-31, from the 10-Q filed Oct 15, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-047271). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,636](/filings/0001493152-26-002286.md) | [1,119](/filings/0001493152-26-016388.md) | [749 d](/filings/0001493152-26-040851.md) | [1,380](/filings/0001493152-26-047271.md) | [1,210](/filings/0001493152-26-002286.md) | [987](/filings/0001493152-26-016388.md) | [875 d](/filings/0001493152-26-040851.md) | [1,265](/filings/0001493152-26-047271.md) | | Gross margin | % | [26.7%](/filings/0001493152-26-002286.md) | [1.7%](/filings/0001493152-26-016388.md) | [(32.6%) d](/filings/0001493152-26-040851.md) | [30.7%](/filings/0001493152-26-047271.md) | [4.2%](/filings/0001493152-26-002286.md) | [(4.5%)](/filings/0001493152-26-016388.md) | [(8.1%) d](/filings/0001493152-26-040851.md) | [8.1%](/filings/0001493152-26-047271.md) | | Operating margin | % | [(60.7%)](/filings/0001493152-26-002286.md) | [(108.1%)](/filings/0001493152-26-016388.md) | [(208.8%) d](/filings/0001493152-26-040851.md) | [(81.0%)](/filings/0001493152-26-047271.md) | [(113.5%)](/filings/0001493152-26-002286.md) | [(131.5%)](/filings/0001493152-26-016388.md) | [(175.2%) d](/filings/0001493152-26-040851.md) | [(97.0%)](/filings/0001493152-26-047271.md) | | Net margin | % | [(58.1%)](/filings/0001493152-26-016388.md) | [(103.9%)](/filings/0001493152-26-016388.md) | [(206.1%) d](/filings/0001493152-26-040851.md) | [0.1%](/filings/0001493152-26-047271.md) | [(109.1%)](/filings/0001493152-26-016388.md) | [(132.9%)](/filings/0001493152-26-016388.md) | [(130.9%) d](/filings/0001493152-26-040851.md) | [(97.4%)](/filings/0001493152-26-047271.md) | | Diluted EPS | $ per share | [(0.06)](/filings/0001493152-26-002286.md) | [(0.48)](/filings/0001493152-26-016388.md) | not reported | [0.00](/filings/0001493152-26-047271.md) | [(0.45)](/filings/0001493152-26-002286.md) | [(0.44)](/filings/0001493152-26-016388.md) | not reported | [(0.37)](/filings/0001493152-26-047271.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-05-31) | FY2023 (2023-05-31) | FY2024 (2024-05-31) | FY2025 (2025-05-31) | FY2026 (2026-05-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.9](/filings/0001493152-23-030254.md) | [5.3](/filings/0001493152-24-034208.md) | [5.4](/filings/0001641172-25-026041.md) | [5.3](/filings/0001493152-26-040851.md) | [4.5](/filings/0001493152-26-040851.md) | | Gross margin | % | [15.8%](/filings/0001493152-23-030254.md) | [8.4%](/filings/0001493152-24-034208.md) | [11.3%](/filings/0001641172-25-026041.md) | [9.4%](/filings/0001493152-26-040851.md) | [8.1%](/filings/0001493152-26-040851.md) | | Operating margin | % | [(24.0%)](/filings/0001493152-23-030254.md) | [(135.3%)](/filings/0001493152-24-034208.md) | [(117.6%)](/filings/0001641172-25-026041.md) | [(96.7%)](/filings/0001493152-26-040851.md) | [(119.5%)](/filings/0001493152-26-040851.md) | | Net margin | % | [(24.0%)](/filings/0001493152-23-030254.md) | [(133.7%)](/filings/0001493152-24-034208.md) | [(110.4%)](/filings/0001641172-25-026041.md) | [(93.6%)](/filings/0001493152-26-040851.md) | [(84.8%)](/filings/0001493152-26-040851.md) | | Diluted EPS | $ per share | [(0.36)](/filings/0001493152-23-030254.md) | [(0.50)](/filings/0001493152-24-034208.md) | [(2.84)](/filings/0001641172-25-026041.md) | [(2.16)](/filings/0001493152-26-040851.md) | [(1.30)](/filings/0001493152-26-040851.md) | | Free cash flow | $m | [(0.5)](/filings/0001493152-23-030254.md) | [(5.5)](/filings/0001493152-24-034208.md) | [(5.4)](/filings/0001641172-25-026041.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bmra/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $42.9k | 24,347 | | Reduced −31,695 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $32.8k | 18,636 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $25.5k | 14,514 | | Unchanged | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $22.2k | 12,640 | | New +12,640 | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $19.1k | 10,849 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $12.2k | 6,951 | | Added +6,432 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $11.6k | 6,613 | | Unchanged | | [NewEdge Advisors, LLC](/funds/1633516.md) | 2026-06-30 | $6.3k | 3,603 | | New +3,603 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $419 | 238 | | New +238 | | [HOLLENCREST CAPITAL MANAGEMENT](/funds/1161722.md) | 2026-06-30 | $352 | 200 | | Reduced −625 | ## Recent filings [All 427 filings](/companies/bmra/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 21:00 ET | [DEF 14A](/filings/0001493152-26-047438.md) | Proxy statement, period 2026-10-16 | 0001493152-26-047438 | | 2026-10-15 | 21:00 ET | [10-Q](/filings/0001493152-26-047271.md) | Quarterly report, period 2026-08-31 | 0001493152-26-047271 | | 2026-10-15 | 21:00 ET | [8-K](/filings/0001493152-26-047270.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-047270 | | 2026-09-28 | 21:00 ET | [10-K/A](/filings/0001493152-26-044621.md) | Annual report, amended, period 2026-05-31 | 0001493152-26-044621 | | 2026-08-31 | 21:00 ET | [10-K](/filings/0001493152-26-040851.md) | Annual report, period 2026-05-31 | 0001493152-26-040851 | | 2026-08-28 | 21:20 ET | [SCHEDULE 13D](/filings/0001213900-26-095193.md) | Ownership report, active investor | 0001213900-26-095193 | | 2026-08-26 | 20:54 ET | [8-K](/filings/0001493152-26-040251.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-040251 | | 2026-06-04 | 20:45 ET | [8-K](/filings/0001493152-26-027290.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001493152-26-027290 | | 2026-04-13 | 21:15 ET | [10-Q](/filings/0001493152-26-016388.md) | Quarterly report, period 2026-02-28 | 0001493152-26-016388 | | 2026-01-14 | 22:15 ET | [10-Q](/filings/0001493152-26-002286.md) | Quarterly report, period 2025-11-30 | 0001493152-26-002286 | ## Latest annual report [Form 10-K for the fiscal year ended May 31, 2026](/filings/0001493152-26-040851.md), filed Aug 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 73290 - Tickers: BMRA - Exchange: Nasdaq - SIC code: 2835 In Vitro & In Vivo Diagnostic Substances - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.